Interventional Evaluation of Monoammonium Glycyrrhizinate-Glycine/DLMethionine Combination Tablets in Mild Alopecia AreataYoshiaki Kubo1*, Toshitatsu Nogita2, Ikuko Kimura3, Mami Chiba4 and Kanako Sakakibara4
- *Corresponding Author:
- Yoshiaki Kubo
Department of Dermatology
Institute of Biomedical Sciences
Tokushima University Graduate School
15-18-3 Kuramoto-cho, Tokushima City
Tokushima 770-8503, Japan
E-mail: [email protected]
Received date: December 28, 2015 Accepted date: January 10, 2016 Published date: January 12, 2016
Citation: Kubo Y, Nogita T, Kimura I, Chiba M, Sakakibara K (2016) Interventional Evaluation of Monoammonium Glycyrrhizinate-Glycine/DLMethionine Combination Tablets in Mild Alopecia Areata. J Clin Exp Dermatol Res 7:322. doi: 10.4172/2155-9554.1000322
Copyright: © 2016 Kubo Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Although monoammonium glycyrrhizinate/glycine/DL-methionine (MG) combination tablets have been widely used widely for the treatment of alopecia areata (AA), there are few studies on efficacious combinations with MG. This study was conducted to determine the efficacy and safety of MG plus 5% carpronium chloride (CC). Methods: In the present interventional study, MG tablets plus 5% carpronium chloride (CC) were compared with CC monotherapy in 31 patients with AA. Results: There were no significant differences in efficacy between the two groups, and the AA area at 8 and 12 weeks was significantly reduced in both. The results of subanalysis stratified by the presence of allergic factors as determined by IgE level showed that there were also significant decreases in the areas of AA 8 and 12 weeks after the start of the combination therapy in patients with allergic factors (p<0.05). No serious adverse events were observed in either group. Conclusion: It is suggested that combination therapy with MG and CC has better therapeutic effects than CC monotherapy, with a significant decrease in the area of AA from 4 weeks of treatment even in mild AA patients with allergic factors.